MedTrace Logo

Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test

NCT01462643 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2011-10-31

No results posted yet for this study

Summary

The aim of the exploratory study is to compare dose related effects of LAS41004 formulations in a non-occlusive PPT.

Conditions

Interventions

DRUG

LAS41004

once daily, topical ointment, 100 microgram per day

Sponsors & Collaborators

  • proDERM GmbH

    collaborator INDUSTRY

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Christoph Willers, MD · Almirall Hermal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01462643 on ClinicalTrials.gov